Renal cancer: from biological heterogeneity to clinical decision-making

Renal cancer comprises a heterogeneous group of solid ma­lig­nan­cies characterized by substantial biological and cli­ni­cal variability, with direct implications for diagnosis, prog­nosis and therapeutic decision-making. Although relatively uncommon compared with other cancers, its clinical impact is disproportionate due to frequent late-stage diagnosis, un­pre­dic­table disease course and the complexity of ma­nage­ment. Recent advances in the understanding of tumor bio­logy have led to major changes in the management of renal cancer, particularly through the development of tar­ge­ted therapies and immunotherapy. These approaches have significantly improved outcomes in advanced disease, while also introducing new challenges related to treatment se­lec­tion, therapeutic sequencing and the management of treat­ment-related toxicity. This review provides a concise and clinically oriented overview of renal cancer, covering the general framework and main subtypes, epidemiology and risk factors, relevant aspects of tumor biology, clinical pre­sen­ta­tion and diagnostic strategies, principles of sta­ging and prognostic assessment, current treatment ap­proa­ches, as well as persisting challenges and grey areas in con­tem­po­rary oncological practice.